Search results
Search results from www.aesgp.eu
| Ingredient | ATC Level 1 | ATC Level 2 | Year Of Switch | Country | Status | Additional Information |
|---|---|---|---|---|---|---|
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Argentina | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Australia | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Austria | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Belgium | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Bulgaria | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | 2014 | Canada | OTC | Maximum daily dose 1mg. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Chile | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | China | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Colombia | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Croatia | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Czech Republic | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Denmark | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Estonia | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Finland | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | France | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Germany | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Greece | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Hungary | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Ireland | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Italy | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Japan | N.R. | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Lithuania | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Mexico | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | New Zealand | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Norway | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Philippines | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Poland | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Portugal | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Romania | Rx | ~Tablet ~Box with 8 PVC-PVDC / Al blisters of 14 tablets/maximum dose of 80 mg should be taken daily, as a single dose or divided into 2 doses given at breakfast or dinner/ 200 mg lovastatin, as a single dose, without side effects clinically significant/The highest dose was 5-6 g. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Russia | — | No information. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Singapore | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Slovak Republic | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Slovenia | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | South Korea | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Spain | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Sweden | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Switzerland | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | The Netherlands | N.R. | Not registered or not marketed. |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | UK | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | USA | Rx | — |
| Lovastatin | C Cardiovascular system. Cardiovascular system | C10. Lipid modifying agents | — | Venezuela | Rx | — |
- 41 ingredients